| Literature DB >> 35889801 |
Natália Maira da Cruz Alves1, Karina Pfrimer1,2, Priscila Carvalho Santos3, Ellen Cristini de Freitas3,4,5, Thiago Neves1, Rodrigo Antônio Pessini6, Márcia Varella Morandi Junqueira-Franco1, Marcello H Nogueira-Barbosa6, Carolyn Anne Greig7, Eduardo Ferriolli1.
Abstract
This study aims to investigate the effects of fish oil supplementation on the muscle adaptive response to resistance exercise training, physical performance and serum levels of inflammatory cytokines in sarcopenic older women. A randomised, double-blind, placebo-controlled trial is performed with thirty-four sarcopenic women (2010 European Consensus of Sarcopenia), aged ≥ 65 years. The participants are allocated into the following two groups: Exercise and Fish Oil (EFO) and Exercise and Placebo (EP). Both groups undertook a resistance exercise programme over 14 weeks. All participants are instructed to ingest 4 g/day of food supplements; the EP group received sunflower oil capsules, and the EFO group, fish oil capsules. The cross-sectional area (CSA) of the quadriceps muscle is calculated using magnetic resonance imaging (MRI). The strength of the lower limbs is measured using isokinetic dynamometry. Both groups show improvements in CSA and strength after the intervention. Changes in EFO are significantly greater compared with EP for muscle strength (peak torque, 19.46 Nm and 5.74 Nm, respectively, p < 0.001). CSA increased after the intervention in both groups (EFO; 6.11% and EP; 2.91%), although there is no significant difference between the groups (p = 0.23). There are no significant intra-group, inter-group or time differences in any of the cytokines measured. The use of fish oil supplementation potentiates the neuromuscular response to the anabolic stimulus from training, increasing muscle strength and physical performance in sarcopenic older women.Entities:
Keywords: aging; fish oil; muscle strength; sarcopenia
Mesh:
Substances:
Year: 2022 PMID: 35889801 PMCID: PMC9317261 DOI: 10.3390/nu14142844
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Figure 1The most prevalent comorbidities were diabetes mellitus and high blood pressure.
General and sociodemographic characteristics of the included volunteers (n = 32).
| Age (Years), Mean (SD) | |
|---|---|
| Age (Years), Mean (SD) | |
| EP | 71.4 (6.21) |
| EFO | 70.6 (3.94) |
| Ethnicity, n (%) | |
| White | 22 (68.7%) |
| Black | 2 (6.25%) |
| Eastern | 8 (25.0%) |
| Marital status, n (%) | |
| Married | 11 (34.4%) |
| Widow | 13 (40.6%) |
| Divorced | 8 (25.0%) |
| Educational level (years), n (%) | |
| 1–4 years | 17 (53.1%) |
| >4 years | 15 (46.9%) |
| Number of medications per day, mean(SD) | |
| EP | 2.7 (3.9) |
| EFO | 2.3 (2.4) |
| Comorbidities, n (%) | |
| High blood pressure | |
| EP | 13 (86.7%) |
| EFO | 14 (82.6%) |
| Diabetes mellitus | |
| EP | 5 (33.3%) |
| EFO | 9 (52.9%) |
EP: Exercise and Placebo Group; EFO: Exercise and Fish Oil Group.
Body composition and height of the participants in the pre- and post-intervention periods (n = 32).
| Group | Pre-Intervention Mean (SD) | Post-Intervention Mean (SD) | Estimated Difference | 95% Confidence Interval | ||
|---|---|---|---|---|---|---|
| Weight (kg) | EP | 57.9 (11.8) | 59.3 (12.5) | −1.3 | −3.03; 0.42 | 0.13 |
| EFO | 62.5 (8.5) | 64.8 (10.7) | −2.4 | −3.99; −0.75 | 0.01 † | |
| Height (m) | EP | 1.52 (0.09) | 1.51 (0.08) | 0.02 | 0.01; 0.03 | 0.00 † |
| EFO | 1.56 (0.06) | 1.55 (0.05) | 0.02 | 0.01; 0.03 | 0.00 † | |
| BMI (kg·m−2) | EP | 24.73 (3.48) | 25.95 (4.21) | −1.22 | −1.97; −0.48 | 0.00 † |
| EFO | 25.58 (3.07) | 27.11(3.95) | −1.53 | −2.23; −0.84 | 0.00 † | |
| SMI (Kg/m−2) | EP | 6.16(0.39) | 7.12 (0.92) | −0.95 | −1.66; −0.25 | 0.01 † |
| EFO | 6.17(0.48) | 8.38(1.52) | −2.21 | −2.86; −1.56 | 0.00 † |
Linear regression mixed effects model. Significance at p < 0.05 level, BMI: body mass index; SMI: skeletal muscle index.
Comparison of changes in physical performance and functional parameters within and between groups (n = 32).
| Group | Pre-Intervention Mean (SD) | Post-Intervention Mean (SD) | |||
|---|---|---|---|---|---|
| HS (kgf) | EP | 18.58 (4.28) | 21.72 (3.00) | 0.000 † | 0.843 |
| EFO | 20.75 (5.47) | 24.14 (4.14) | |||
| GS (m/s) | EP | 1.22 (0.48) | 1.36 (0.41) | 0.059 | 0.655 |
| EFO | 1.11 (0.38) | 1.19 (0.35) | |||
| 6mWT (m) | EP | 376.60 (107.2) | 377.20 (105.5) | 0.008 † | 0.009 † |
| EFO | 378.20 (60.64) | 443.10 (101.6) | |||
| MQ (Nm/cm2) | EP | 18.54 (4.44) | 19. 32 (5.05) | 0.002 † | 0.004 † |
| EFO | 17.77 (4.72) | 19.92 (4.38) | |||
| Power (watts) | EP | 31.7 (10.5) | 33.0 (14.2) | 0.641 | 0.635 |
| EFO | 31.5 (9.07) | 29.9 (12.6) | |||
| Peak Torque | EP | 63.92 (19.48) | 69.66 (21.84) | 0.000 † | 0.003 † |
| EFO | 59.75 (24.59) | 79.21 (18.39) |
GLM repeated ANOVA, † Significance at p < 0.05, HS: Handgrip Strength; GS: Gait Speed; 6 mWT: six-minute walking test; MQ: muscle quality. * GLM repeated ANOVA was used to identify differences between factors group and time (pre and posttraining).
Plasma concentration of inflammatory cytokines before and after the intervention (n = 32).
| Group | Pre-Intervention Mean (SD) | Post-Intervention Mean (SD) | Estimated | 95% Confidence Interval | ||
|---|---|---|---|---|---|---|
| IL1β | EP | 0.87 (0.91) | 0.73 (0.54) | 0.13 | −0.22; 0.49 | 0.45 |
| EFO | 0.68 (0.57) | 0.67 (0.28) | 0.01 | −0.33; 0.35 | 0.94 | |
| IL6 | EP | 2.72 (2.35) | 1.93 (1.86) | 0.79 | −0.93; 2.51 | 0.36 |
| EFO | 5.55 (7.02) | 4.19 (5.68) | 1.36 | −0.31; 3.02 | 0.11 | |
| IL8 | EP | 4.48 (1.79) | 5.82 (5.44) | −1.34 | −3.89; 1.21 | 0.29 |
| EFO | 5.09 (3.59) | 5.45 (2.96) | −0.35 | −2.82; 2.11 | 0.77 | |
| IL10 | EP | 4.20 (3.95) | 10.41 (26.41) | −6.20 | −16.14; 3.73 | 0.21 |
| EFO | 4.48 (3.27) | 4.09 (3.39) | 0.32 | −9.29; 9.95 | 0.94 | |
| TNFα | EP | 13.70 (7.15) | 13.39 (5.94) | 0.31 | −2.97; 3.59 | 0.85 |
| EFO | 15.63 (6.40) | 14.77 (6.14) | 0.86 | −2.32; 4.04 | 0.58 |
Linear regression mixed effects model.
Figure 2Cross-sectional area of the quadriceps muscle of both groups in the pre- and post-intervention period. GLM repeated measures ANOVA.